Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists

Molecular and Cellular Endocrinology

Volumn 381, Issue 1-2, 2013, Pages 26-34

  O'Harte, F P M ^a   Franklin, Z J ^a   Rafferty, E P ^a   Irwin, N ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Acylation; Diabetes; Glucagon; Glucagon receptor antagonist; Peptide analogue; Therapy

Indexed keywords

CYCLIC AMP; DES 1 HISTIDINE 4 PROLINE 9 GLUTAMIC ACID 12 LYSINE FA GLUCAGON; DES 1 HISTIDINE 4 PROLINE 9 GLUTAMIC ACID 30 LYSINE FA GLUCAGON; DES 1 HISTIDINE 4 PROLINE 9 GLUTAMIC ACID GLUCAGON; DES 1 HISTIDINE 4 PROLINE GLUCAGON; DIPEPTIDYL PEPTIDASE IV; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON RECEPTOR; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; ENZYME DEGRADATION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ACYLATION; DIABETES; FA; FATTY ACID; GLUCAGON; GLUCAGON RECEPTOR ANTAGONIST; PEPTIDE ANALOGUE; THERAPY;

ANIMALS; BLOOD GLUCOSE; CELL LINE; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DRUG EVALUATION, PRECLINICAL; GLUCAGON; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, OBESE; PROTEOLYSIS; RECEPTORS, GLUCAGON;

EID: 84882740205     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.07.014     Document Type: Article

References (46)

1. Ahn J.M., Medeiros M., Trivedi D., Hruby V.J. Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4. Pept. Res. 2001, 58:151-158.
2. Ali S., Drucker D.J. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E415-E421.
3. Bailey C.J., Flatt P.R., Atkins T.W. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 1982, 6:11-21.
4. Baron A.D., Schaeffer L., Shragg P., Kolterman O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987, 36:274-283.
5. Corvera S., Huerta-Bahena J., Pelton J.T., Hruby V.J., Trivedi D., García-Sáinz J.A. Metabolic effects and cyclic AMP levels produced by glucagon, (1-N alpha-Trinitrophenylhistidine,12-homoarginine)glucagon and forskolin in isolated rat hepatocytes. Biochim. Biophys. Acta 1984, 804:434-441.
6. Deacon C.F., Pridal L., Klarskov L., Olesen M., Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. 1996, 271:E458-E464.
7. Emmanouel D.S., Jaspan J.B., Rubenstein A.H., Huen A.H., Fink E., Katz A.I. Glucagon metabolism in the rat. J. Clin. Invest. 1978, 62:6-13.
8. Estall J.L., Drucker D.J. Glucagon and glucagon-like peptide receptors as drug targets. Curr. Pharm. Des. 2006, 12:1731-1750.
9. Farhy L.S., McCall A.L. Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency. Diabetes Obes. Metab. 2011, 13:133-143.
10. Flatt P.R., Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20:573-577.
11. Flatt P.R., Bailey C.J., Buchanan K.D. Regulation of plasma immunoreactive glucagon in obese hyperglycaemic (ob/ob) mice. J. Endocrinol. 1982, 95:215-227.
12. Franklin Z., Rafferty E.P., Irwin N., O'Harte F.P.M. Peptide based glucagon analogues are effective agents in blocking the hyperglycaemic actions of glucagon in high fat fed mice. Regul. Pept. 2010, 164(S22):32. (Abstract).
13. García-Sáinz J.A., Mendlovic F., Martínez-Olmedo M.A. Effects of phorbol esters on alpha 1-adrenergic-mediated and glucagon-mediated actions in isolated rat hepatocytes. Biochem. J. 1985, 228:277-280.
14. Gault V.A., O'Harte F.P.M., Harriott P., Flatt P.R. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 2002, 290:1420-1426.
15. Gault V.A., Kerr B.D., Harriott P., Flatt P.R. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity. Clin. Sci. (Lond.) 2011, 121:107-117.
16. Gelling R.W., Du X.Q., Dichmann D.S., Romer J., Huang H., Cui L., Obici S., Tang B., Holst J.J., Fledelius C., Johansen P.B., Rossetti L., Jelicks L.A., Serup P., Nishimura E., Charron M.J. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. USA 2003, 100:1438-1443.
17. Green B.D., Flatt P.R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21:497-516.
18. Grossman S. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide. Pharmacotherapy 2009, 29:25S-32S.
19. Gustavsson N., Seah T., Lao Y., Radda G.K., Südhof T.C., Han W. Delayed onset of hyperglycaemia in a mouse model with impaired glucagon secretion demonstrates that dysregulated glucagon secretion promotes hyperglycaemia and type 2 diabetes. Diabetologia 2011, 54:415-422.
20. Hinke S.A., Pospisilik J.A., Demuth H.U., Mannhart S., Kühn-Wache K., Hoffmann T., Nishimura E., Pederson R.A., McIntosh C.H.S. Dipeptidyl peptidase IV (DPPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPPIV-resistant analogs. J. Biol. Chem. 2000, 275:3827-3834.
21. Holst J.J. Degradation of Bioactive Substances: Physiology and Pathophysiology 1991, 167-180. CRC Press, Inc., Boca Raton, FL, USA. J. Henriksen (Ed.).
22. Hruby V.J. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs. Mol. Cell. Biochem. 1982, 44:49-64.
23. 37). Biol. Chem. 2005, 386:679-687.
24. Irwin N., Clarke G.C., Green B.D., Greer B., Harriott P., Gault V.A., O'Harte F.P.M., Flatt P.R. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem. Pharmacol. 2006, 72:719-728.
25. Irwin N., Gault V., Flatt P.R. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?. Expert Opin. Invest. Drugs 2010, 19:1039-1048.
26. Kerr B.D., Irwin N., O'Harte F.P.M., Bailey C.J., Flatt P.R., Gault V.A. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem. Pharmacol. 2009, 78:1008-1016.
27. Kim R.M., Chang J., Lins A.R., Brady E., Candelore M.R., Dallas-Yang Q., Ding V., Dragovic J., Iliff S., Jiang G., Mock S., Qureshi S., Saperstein R., Szalkowski D., Tamvakopoulos C., Tota L., Wright M., Yang X., Tata J.R., Chapman K., Zhang B.B., Parmee E.R. Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18:3701-3705.
28. Knop F.K., Aaboe K., Vilsbøll T., Vølund A., Holst J.J., Krarup T., Madsbad S. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes. Metab. 2012, 14:500-510.
29. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., Thøgersen H., Wilken M., Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000, 43:1664-1669.
30. Lau J., Behrens C., Sidelmann U.G., Knudsen L.B., Lundt B., Sams C., Ynddal L., Brand C.L., Pridal L., Ling A., Kiel D., Plewe M., Shi S., Madsen P. New beta-alanine derivatives are orally available glucagon receptor antagonists. J. Med. Chem. 2007, 50:113-128.
31. Lee J., Lee C., Kim I., Moon H.R., Kim T.H., Oh K.T., Lee E.S., Lee K.C., Youn Y.S. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int. J. Pharm. 2012, 424:50-57.
32. Liang R., Abrardo L., Brady E.J., Candelore M.R., Ding V., Saperstein R., Tota L.M., Wright M., Mock S., Tamvakopolous C., Tong S., Zheng S., Zhang B.B., Tata J.R., Parmee E.R. Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor. Bioorg. Med. Chem. Lett. 2007, 17:587-592.
33. Madsen P., Kodra J.T., Behrens C., Nishimura E., Jeppesen C.B., Pridal L., Andersen B., Knudsen L.B., Valcarce-Aspegren C., Guldbrandt M., Christensen I.T., Jørgensen A.S., Ynddal L., Brand C.L., Bagger M.A., Lau J. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. J. Med. Chem. 2009, 52:2989-3000.
34. Mu J., Qureshi S.A., Brady E.J., Muise E.S., Candelore M.R., Jiang G., Li Z., Wu M.S., Yang X., Dallas-Yang Q., Miller C., Xiong Y., Langdon R.B., Parmee E.R., Zhang B.B. Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One 2012, 7:e49572.
35. Pospisilik J.A., Hinke S.A., Pederson R.A., Hoffman T., Rosche F., Schlenzig D., Glund K., Heiser U., McIntosh C.H.S., Demuth H.U. Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul. Pept. 2001, 96:133-141.
36. Qureshi S.A., Rios Candelore M., Xie D., Yang X., Tota L.M., Ding V.D., Li Z., Bansal A., Miller C., Cohen S.M., Jiang G., Brady E., Saperstein R., Duffy J.L., Tata J.R., Chapman K.T., Moller D.E., Zhang B.B. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004, 53:3267-3273.
37. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., Jaspan J.B. Documentation of hyperglucagonaemia throughout the day in non-obese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1987, 64:106-110.
38. Rodgers R.L. Glucagon and cyclic AMP: time to turn the page?. Curr. Diabetes Rev. 2012, 8:362-381.
39. Sloop K.W., Michael M.D., Moyers J.S. Glucagon as a target for the treatment of Type 2 diabetes. Expert Opin. Ther. Targets 2005, 9:593-600.
40. Tan K., Tsiolakis D., Marks V. Effect of glucagon antibodies on plasma glucose, insulin and somatostatin in the fasting and fed rat. Diabetologia 1985, 28:435-440.
41. Unson C.G., Andreu D., Gurzenda E.M., Merrifield R.B. Synthetic peptide antagonists of glucagon. Proc. Natl. Acad. Sci. USA 1987, 84:4083-4087.
42. 9]glucagon amide, a glucagon antagonist. Peptides 1989, 10:1171-1177.
43. Unson C.G., Macdonald D., Ray K., Durrah T.L., Merrifield R.B. Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. J. Biol. Chem. 1991, 266:2763-2766.
44. Unson C.G., Macdonald D., Merrifield R.B. The role of histidine-1 in glucagon action. Arch. Biochem. Biophys. 1993, 300:747-750.
45. Unson C.G., Wu C.R., Cheung C.P., Merrifield R.B. Positively charged residues at position 12, 17 and 18 of glucagon ensure maximum biological potency. J. Biol. Chem. 1998, 273:10308-10312.
46. Vilsbøll T., Holst J.J., Knop F.K. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:453-462.